Last reviewed · How we verify
CVL-751
At a glance
| Generic name | CVL-751 |
|---|---|
| Sponsor | Cerevel Therapeutics, LLC |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Open-label Trial in Parkinson's Disease (PD) (PHASE3)
- Flexible-Dose Trial in Early Parkinson's Disease (PD) (PHASE3)
- Fixed-Dose Trial in Early Parkinson's Disease (PD) (PHASE3)
- Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson's Disease With Motor Fluctuations (TEMPO-3) (PHASE3)
- To Evaluate Pharmacokinetics (PK) and Safety of Tavapadon in Participants With Severe Renal Impairment Compared to Participants With Normal Renal Function (PHASE1)
- Multiple-dose Trial to Determine the Clinical Bioequivalence Between Tavapadon Tablets in Participants With Parkinson's Disease (PHASE1)
- To Evaluate the Pharmacokinetics (PK) and Safety of Tavapadon in Participants With Mild and Moderate Hepatic Impairment Compared to Participants With Normal Hepatic Function (PHASE1)
- Study to Evaluate the Effects of Cytochrome P450 (CYP) 3A4 Inducer Carbamazepine on Tavapadon Pharmacokinetics in Healthy Adult Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CVL-751 CI brief — competitive landscape report
- CVL-751 updates RSS · CI watch RSS
- Cerevel Therapeutics, LLC portfolio CI